UA114FE

UA114FE is an investigational drug candidate under development by Aucta Pharmaceuticals, a specialty pharmaceutical company focused on the 505(b)(2) and ANDA regulatory pathways. The drug is positioned within the company's neurology pipeline. While the specific active pharmaceutical ingredient and the exact neurological indication have not been publicly disclosed, Aucta's business model typically involves the development of improved formulations, such as new dosage forms or delivery systems, for established drug molecules. As of the current pipeline reports, UA114FE remains in the development stage for neurological disorders.